click below
click below
Normal Size Small Size show me how
Stack #4726101
| Question | Answer |
|---|---|
| Anticoagulants — purpose | Prevent formation or extension of blood clots by interfering with the coagulation process. |
| Heparin — action | Enhances antithrombin activity, which inhibits clotting factors and reduces thrombin formation. |
| Heparin — monitoring | Heparin therapy is commonly monitored with aPTT. |
| Warfarin — action | Inhibits vitamin K-dependent clotting factor production, reducing coagulation. |
| Warfarin — monitoring | Warfarin therapy is monitored with PT/INR. |
| Heparin vs Warfarin | Heparin works rapidly and is monitored with aPTT; warfarin acts more slowly and is monitored with PT/INR. |
| Antiplatelet drugs — purpose | Prevent platelets from sticking together and forming a platelet plug. |
| Aspirin — action | Inhibits platelet aggregation, reducing platelet plug formation. |
| Clopidogrel — action | Inhibits platelet activation and aggregation, reducing arterial clot formation. |
| Thrombolytics — purpose | Break down an existing clot by promoting fibrin breakdown. |
| tPA — action | Converts plasminogen to plasmin, which breaks down fibrin in a clot. |
| Anticoagulant vs antiplatelet | Anticoagulants interfere with clotting factors; antiplatelets inhibit platelet aggregation. |
| Anticoagulant vs thrombolytic | Anticoagulants prevent or limit clot formation; thrombolytics actively break down existing clots. |
| Clotting medication danger | The major risk of anticoagulant, antiplatelet, and thrombolytic therapy is excessive bleeding. |
| Heparin overdose effect | Excessive heparin can greatly increase anticoagulation and cause bleeding. |
| Warfarin overdose effect | Excessive warfarin raises INR and increases bleeding risk. |
| Heparin vs Warfarin mechanism | Heparin acts on clotting factors already in circulation; warfarin decreases production of vitamin K-dependent factors. |
| Small-cell lung carcinoma | Associated with SIADH, which can cause hyponatremia from inappropriate ADH secretion. |
| Squamous cell carcinoma | Can produce parathyroid hormone-related peptide, causing hypercalcemia. |
| HPV and cancer | Human papillomavirus is strongly associated with cervical cancer. |
| HBV/HCV and cancer | Chronic hepatitis B or C infection increases risk of hepatocellular carcinoma. |
| EBV and cancer | Epstein-Barr virus is associated with Burkitt lymphoma. |
| Kaposi sarcoma | A malignancy associated with severe immunosuppression, especially AIDS; involves vascular tissue. |
| Non-Hodgkin lymphoma | A malignancy that can occur as an opportunistic cancer in advanced HIV/AIDS. |
| Melanoma | Malignant tumor of melanocytes that can invade and metastasize. |
| Cancer angiogenesis | Tumors release VEGF to stimulate new blood vessel growth and obtain nutrients. |
| Cancer metastasis | Malignant cells spread from the primary tumor to distant tissues through blood or lymphatic vessels. |
| Benign vs malignant | Benign tumors are localized and non-invasive; malignant tumors invade surrounding tissue and may metastasize. |
| Anaplasia | Loss of cellular differentiation; poorly differentiated or undifferentiated cells are associated with malignancy. |